News - Asia-Pacific, Bristol-Myers Squibb

Filter

Popular Filters

Bristol-Myers Squibb and Samsung BioLogics expand manufacturing deal

23-04-2014

US drug major Bristol-Myers Squibb and South Korea’s Samsung BioLogics revealed that they will increase…

Asia-PacificBiotechnologyBristol-Myers SquibbProductionSamsung BioLogics

Bristol-Myers Squibb extends distribution in six Asian markets

Bristol-Myers Squibb extends distribution in six Asian markets

08-04-2014

US drug major Bristol-Myers Squibb has extended its relationship with DKSH, a market expansion services…

Asia-PacificBristol-Myers SquibbMarkets & MarketingPharmaceutical

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

31-03-2014

Multinational drugmakers might be crying themselves hoarse that India does not protect innovation - that…

Asia-PacificBristol-Myers SquibbFinancialGlaxoSmithKlineIndiaMerck & CoMergers & AcquisitionsMylan LaboratoriesPatentsPharmaceuticalSanofi

Ono Pharma files for approval of nivolumab for melanoma in Japan

30-12-2013

Japanese drugmaker Ono Pharmaceutical has filed an application to obtain a manufacturing and marketing…

Asia-PacificBristol-Myers SquibbnivolumabOncologyOno PharmaceuticalPharmaceuticalRegulation

Novel oral anticoagulants will continue to drive atrial fibrillation drug market growth

20-12-2013

The atrial fibrillation drug market will experience continued growth through the rest of the decade,…

Asia-PacificBayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisEuropeMarkets & MarketingNorth AmericaPfizerPharmaceuticalPradaxaXarelto

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

Bristol-Myers files for Japanese approval of first all-oral, interferon/ribavirin-free hep C treatment

03-11-2013

US drug major Bristol-Myers Squibb has filed a New Drug Application with Japan’s Pharmaceutical and…

Anti-viralsAsia-PacificasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalRegulation

Growth drivers for China's type 2 diabetes market

09-08-2013

The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Bristol-Myers partners with South Korean firm on biopharma production

29-07-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) has entered into a 10-year agreement under which Samsung…

Asia-PacificBiotechnologyBristol-Myers SquibbOncologyPharmaceuticalProductionSamsung BioLogics

Bristol-Myers and Simcere agree to co-develop/commercialize Orencia SC in China

14-06-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) and China-based Simcere Pharmaceutical (NYSE: SCR) have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyBristol-Myers SquibbLicensingOrenciaPharmaceuticalSimcere Pharmaceutical

CML drug revenue in Japan to grow, despite global decline, says GlobalData

21-05-2013

Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Merck KGaA links with Bristol-Myers for Glucophage promotion in China

19-03-2013

German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib

15-01-2013

The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27-12-2012

Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Otsuka sells on Japanese saxagliptin rights to Kyowa Hakko

03-07-2012

Japanese drugmakers Otsuka Pharmaceutical (TYO: 4578) and Kyowa Hakko Kirin (TYO: 4151) have entered…

Asia-PacificBristol-Myers SquibbDiabetesKyowa Hakko KirinLicensingOncologyOtsukaPharmaceuticalResearchsaxagliptin

Bristol-Myers gets more rights to Ono antibody in exchange for Japan co-rights to Orencia

22-09-2011

US drug major Bristol-Myers Squibb (NYSE:BMY) says it has agreed with Japan’s Ono Pharmaceutical…

Anti-Arthritics/RheumaticsAsia-PacificBristol-Myers SquibbLicensingMarkets & MarketingOncologyOno PharmaceuticalOrenciaPharmaceutical

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top